- Open Access
Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy
Biomarker Research volume 11, Article number: 22 (2023)
Galectins are animal lectins with specific affinity for galactosides via the conserved carbohydrate recognition domains. Increasing studies recently have identified critical roles of galectin family members in tumor progression. Abnormal expression of galectins contributes to the proliferation, metastasis, epithelial-mesenchymal transformation (EMT), immunosuppression, radio-resistance and chemoresistance in various cancers, which has attracted cumulative clinical interest in galectin-based cancer treatment. Galectin family members have been reported to participate in autophagy regulation under physiological conditions and in non-tumoral diseases, and implication of galectins in multiple processes of carcinogenesis also involves regulation of autophagy, however, the relationship between galectins, autophagy and cancer remains largely unclear. In this review, we introduce the structure and function of galectins at the molecular level, summarize their engagements in autophagy and cancer progression, and also highlight the regulation of autophagy by galectins in cancer as well as the therapeutic potentials of galectin and autophagy-based strategies. Elaborating on the mechanism of galectin-regulated autophagy in cancers will accelerate the exploitation of galectins-autophagy targeted therapies in treatment for cancer.
Galectins (Gals), first characterized in the mid-1970s , were initially referred to as S-type lectins due to their sulfhydryl dependence and were then defined as galectins in 1994 . Galectins possess multiple functions, including mediating cell–cell and cell–matrix adhesion, regulating cell growth, apoptosis, pre-mRNA splicing, signal transduction, and immune regulation . They are widely expressed in various cell types and are renowned for their capacity to increase cancer cell invasiveness and resistance to chemotherapy . Alterations in galectin expression are closely related to cancer biology including vascular formation, cell migration, and tumor immune evasion during carcinogenesis . In most cases, the upregulated expression of galectin in the tumor microenvironment predicts a poor prognosis . Therefore, galectins have drawn particular attention in cancer research and therapy.
Notably, galectins are recently shown to be associated with autophagy regulation in different cancers. For decades, autophagy, a natural and conserved degradation form of cell, has been widely reported to maintain intracellular homeostasis under physiological and pathological conditions, and dysregulation of autophagy is associated with a variety of diseases (e.g., cancer, neurodegenerative diseases, type II diabetes, and heart disease) [6, 7]. Particularly in cancer, autophagy not only suppresses tumors by removing damaged organelles and restricting cell proliferation by destabilizing the genome, but also facilitates tumor growth by satisfying the metabolic demands of cancer cells and inducing chemoresistance, promoting cross-talk between tumor cell and stroma, especially in nutrient-limited microenvironments [8, 9]. Although considerable numbers of autophagy-related genes have now been discovered, the mechanisms of autophagy-related signaling and how these pathways impact cancer biology are still controversial due to that the roles of autophagy are largely depending on the tumorigenesis stage and the tumor type.
The association of galectins and autophagy in carcinogenesis has been evidenced by growing studies showing that the aberrant expression of galectins enhances the dependence of cancer cells on autophagy. It is believed that inhibiting autophagy and galectins activities in specific types of tumors may serve as useful supplement to current therapies. In this review, we enumerate the current understanding of galectins and autophagy in cancer, summarize the recent advances in potential therapeutic approaches related to galectin and autophagy regulation in cancer, with particular focus on the current use of galectin inhibitors and autophagy modulators in cancer therapy. Lastly, we prospect the challenges and therapeutic opportunities of galectin and autophagy targeted strategies in future clinical applications.
Overview of galectins
Galectin structure and classification
Galectins are a class of glycan-binding proteins consisting of one or two conserved carbohydrate recognition domains (CRDs) containing approximately 130 amino acids . Galectin homologues are highly conserved in primitive organisms such as sponges and nematodes. There are 16 different galectins identified in mammals, and 12 of them have been founded in humans except galectin-5, -6, -11 and -15 (Table 1) . Galectins are often divided into three subgroups based on their distinct biochemical structural characteristics: prototypical galectins have one CRD per subunit and may present as noncovalently linked homodimers (galectin-1, -2, -5, -7, -10, -11, -13, -14,-15 and -16); the tandem-repeat type galectins contain two homologous CRDs that are joined by a functional linker peptide (galectin-4, -6, -8, -9 and -12); the chimera type galectin (galectin-3) contains a non-lectin N-terminal region connected to a CRD [4, 12] (Fig. 1.). Each galectin has an individual carbohydrate binding preference, due to its bivalent or multivalent interactions with glycans . It is noteworthy that not all galectins have the ability to bind to glycans. For example, Gal-10 can bind to eosinophilic granule cationic ribonucleases without the help of carbohydrates , and Gal-13 does not bind to β-galactosides and forms dimers via intermolecular disulfide bridges .
Cellular functions of galectin
As a soluble protein, galectin plays key regulatory roles both inside and outside of the cell. Intracellular galectins exhibit cellular functions such as regulation of cell growth and apoptosis in a carbohydrate-independent manner and modulate intracellular signaling pathways through protein–protein interactions with other cytoplasmic and nuclear proteins . Although lacking the typical secretory signaling peptides, galectins can be secreted to extracellular space through non-classical secretory pathways. For instance, Epstein-Barr virus (EBV) infected nasopharyngeal carcinoma cells release Gal-9 via exosomes . Secreted galectins can regulate cell adhesion, migration and invasion by recognizing and binding to carbohydrates of glycoproteins or glycolipids . In tumor cells, the function of galectins relates to their subcellular localization. The intracellular galectins enhance oncogenic signaling and reduce apoptosis, promote proliferation of tumor cells , while the extracellular galectins, on the other hand, bind to glycoconjugate ligands on surrounding cells and finally regulate the immune responses and tumor growth [23, 24].
Role of galectin in tumor progression
Studies have shown that galectins play vital roles in multiple processes (e.g. tumorigenesis, metastasis and angiogenesis) of tumor progression. Interestingly, galectins possess diverse functions in different tumors (Table 2) and regulate tumor progression through distinct mechanisms.
Gal-1 was the first identified member in the galectin family, and the carbohydrate-binding action of Gal-1 occurs extracellularly while the biological functions of Gal-1 depend on its cellular localization and local concentration . The dysregulated expression of Gal-1 in tumors has been widely reported and it is considered as a biomarker for malignant progression in urothelial urinary bladder carcinoma and carcinoma of the aerodigestive tract [25,26,27]. Gal-1 is expressed and secreted by numerous tumors such as gastric, hepatocellular, pancreatic, colorectal, prostate, neuroblastoma, glioma, aggressive melanoma, osteosarcoma, breast, lung, bladder, thyroid, ovarian epithelial, myeloma, head and neck, cervical, and endometrial cancers [16, 28]. Elevated Gal-1 expression in tumor correlates with multiple processes including cell cycle regulation, apoptosis, cell adhesion, migration, angiogenesis, drug resistance and immunosuppression by interacting with glycoconjugates and regulating the biological activities of H-Ras/MEK/ERK, β-catenin pathways in the tumor microenvironment [5, 28]. The role of Gal-1 in mediating tumor growth and metastasis has also been verified in tumor-bearing animal models, which further indicates that inhibition of Gal-1 may serve as a promising strategy for cancer therapy .
Gal-3, initially named CBP35 in 1983, is the only chimeric galectin discovered in vertebrates as well as one of the most intensively studied galectins . In addition to various biological functions including neurogenesis and inflammation under physiological conditions, Gal-3 has been reported to be associated with cancer cell proliferation, migration, invasion, angiogenesis and immunosuppression through mechanisms that Gal-3 regulates M2 polarization of macrophages, triggers apoptosis by binding to antitumor T cells, induces the expression of matrix metalloproteinases through p38-MAPK pathway, maintains mitochondrial homeostasis and regulates tumor metabolism. [16, 31]. Gal-3 in the cytoplasm is involved in the regulation of many cancer-related signaling pathways involving oncogenes such as RAS, BCL-2 and MYC [32,33,34]. In addition, intracellular Gal-3 can inhibit the mitochondrial apoptotic pathway induced by cisplatin or etoposide in prostate and breast cancer cells [32, 35]. Given that inhibition of Gal-3 may be crucial to increase the sensitivity of tumor cells to chemotherapy, the role of Gal-3 in chemoresistance is also of interest . Recent studies suggest that upregulation of Gal-3 is positively correlated with tumor progression and metastasis in a variety of cancers, including breast cancer, glioma, thyroid cancer, gastric cancer, lung cancer, kidney cancer, prostate cancer, melanoma, ovarian cancer, cervical cancer, bladder cancer and pancreatic cancer [16, 17, 37,38,39]. In addition to tumor cells, the tumor microenvironment induces Gal-3 expression to maintain cellular homeostasis and promote tumor growth as well . For example, Gal-3 is enriched in hypoxic regions and promotes malignancy under hypoxia in glioblastoma, breast cancer and non-small cell lung cancer [41, 42]. Notably, Gal-3 in the tumor microenvironment has distinct roles when located intracellularly and extracellularly . When accumulated in the nucleus, Gal-3 shows anticancer action; but it promotes tumor growth when expressed in the cytoplasm in tongue cancer and prostate cancer cells [44, 45].
Hadari and colleagues in 1995 first identified the ‘tandem repeat’-type galectin Gal-8 , which was then isolated from the prostate [PCTA-1] and the lung Po66 carbohydrate-binding protein (Po66-CBP) [47, 48]. Gal-8 is widely expressed in normal tissues, whereas increased expression is present in breast cancer, laryngeal cancer and cutaneous lymphoma, with decreased expression in skin cancer and several gastrointestinal cancers including pancreatic, liver and colon cancers [49,50,51,52,53]. Intriguingly, Gal-8 is expressed only in tumor prostate cells other than normal prostate tissue, implying its potential as a specific biomarker for prostate cancer . Gal-8 has also been reported to involved in tumor cell proliferation, adhesion, migration and EMT in lung cancer, breast cancer, ovarian cancer, and malignant glioma [17, 38, 55,56,57]. Mechanically, Gal-8 regulates the adhesion and migration of lung cancer cells by binding to integrins and activates the downstream focal adhesion kinase (FAK) pathway , promoting breast cancer cell migration through interacting with activated leukocyte cell adhesion molecule such as CD166/ALCAM receptors .
Gal-9 is of particular interest due to its multiple biological functions and potent immunomodulatory effects. In 1997, Gal-9 was initially isolated from mouse embryonic kidney , and it was found to be an autoantigen linked to Hodgkin's lymphoma and a novel eosinophil chemotactic agent produced by T cells [59, 60]. Gal-9 was highly expressed in Hodgkin's lymphoma, colorectal, oral and pancreatic cancers, whereas expressed at a low level in breast cancer, liver cancer, lung cancer, prostate cancer, renal cancer and melanoma . In solid tumors, Gal-9 expression is closely related to cell proliferation and metastasis via JNK and p38 MAP kinase pathways, mitochondrial pathway, blockade of adhesion to the endothelium and extracellular matrixes. Gal-9 can induces apoptosis in esophageal cancer cells, myeloma cells, bile duct cancer cells and ovarian cancer cells [61,62,63,64]. In breast cancer and malignant melanoma, overexpression of cytoplasmic Gal-9 may inhibit tumor metastasis and attenuate recurrence . More recently, Gal-9 indicates emerging potential as a therapeutic target for cancers, by serving as a good prognostic factor for kidney cancer and an independent indicator of poor prognosis in glioma [38, 66]. Gal-9 also possesses immunomodulatory effects by serving as a ligand for T-cell immunoglobulin and mucin structural domain protein 3 (Tim-3), which are crucial for anticancer immunity . Notably, combined inhibition of Gal-9 and immune checkpoint protein programmed cell death ligand 1 (PD-L1) in glioblastoma is expected to overcome the failure of mono-target immunotherapy .
Few studies have focused on the phenotype and function of altered Gal-2 expression in cancers versus normal tissues. Increased circulating levels of Gal-2 have been reported in the serum of patients with colon and breast cancers . Encouragingly, Gal-2 was recently identified as an immunotherapeutic target for triple-negative breast cancer using an in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based screening .
Gal-4 was first found in porcine oral epithelium and rat intestine [69, 70]. Despite abundant expression in the luminal epithelium of the gastrointestinal tract , Gal-4 was found upregulated in the corresponding cancerous tissues, such as the liver, mammary gland, ovary, and brain . Recent data showed that Gal-4 was highly enriched in the serum of patients with cervical cancer . Interestingly, Gal-4 has tumor suppressive effects in colorectal and pancreatic adenocarcinomas [74, 75], whereas it is an unfavorable prognosis factor in patients with lung adenocarcinomas . Moreover, Gal-4 interacts with and down-regulates the functions of Wnt signaling pathway and interferes with the integrin β4/Src/FAK cascade.
Gal-7 is a transcriptional target of the tumor suppressor protein p53 and was initially identified by Magnaldo et al. in 1995 . Gal-7 is highly expressed in breast cancer, thyroid cancer and pharynx cancer, however, its expression is lower in stomach cancer, colon cancer, cervical squamous cancer and uroepithelial bladder cancer . Gal-7 can serve as a prognostic marker for epithelial ovarian cancer . Moreover, Gal-7 is a negative growth regulator in neuroblastoma and may predict chemoresistance in pancreatic cancer [79, 80].
Other mammalian galectins including Gal-10, Gal-12, Gal-13, Gal-14, and Gal-16 were relatively less investigated in cancers. Gal-10 was reported to be associated with colon cancer and gastric cancer [84, 85]. Down-regulation of Gal-12 is observed in colon cancer with a tumor suppressive function by binding to SLC1A5 and suppressing glutamine anaplerosis . Findings regarding Gal-13, Gal-14 and Gal-16 are mainly limited to placental tissues. It is worth noting that, despite the lack of studies including normal tissues as control, these three galectins are believed to participate in cancer biology [18, 19]. In conclusion, these findings together strongly support the essential roles of galectin family members in carcinogenesis, further highlighting the basis for galectin-targeted cancer therapy as demonstrated below.
Targeting galectin for cancer therapy
The development of galectin inhibitors started decades ago when the essential roles of galectins in tumor growth were initially discovered. So far, two major groups of galectin inhibitors are available: carbohydrate-based and non-carbohydrate inhibitors . Carbohydrate inhibitors include glycodimers and modified glycans such as inhibitors based on galactose, talose, lactose, N-acetylamino lactose, and thiogalactoside ; non-carbohydrate inhibitors include peptides, peptidomimetic inhibitors and heterocyclic compounds . Currently, typical inhibitors targeting Gal-1 (Table 3) and Gal-3 (Table 4) have already shown significant potential in clinical applications of cancer therapy.
Thiobisgalactoside (TDG) is a synthetic disaccharide targeting Gal-1 . Modified citrus pectin (MCP, PectaSol-C), RN1 and GM-CT-01 (DAVANAT) are natural polysaccharides evidenced to have galectin inhibiting activity, by which MCP and RN1 inhibit Gal-3 function, and GM-CT-01 has affinity for both Gal-1 and Gal-3 [91, 95]. A modified DAVANAT version, Gal-3 inhibitor GR-MD-02, was shown to be effective in treating mouse nonalcoholic steatohepatitis . Novel Gal-3 inhibitor GCS-100, a polysaccharide derived from citrus pectin, exhibits potential effects in treatment for myeloma . A synthetic peptide named Anginex specifically binds to Gal-1 and exerts antiangiogenic and antitumor effects . The non-peptide compound OTX008 targets against Gal-1 and inhibits tumor cell proliferation, cell cycle, and angiogenesis . Diphenyl sulfone (DBF) is a partial peptidomimetic agent and its derivative 6DB7 designed to inhibit Gal-1 also suppresses angiogenesis in tumor tissue . Recently, a preclinical evaluation of GB1107 and TD139, inhibitors of Gal-3, revealed promising outcomes in the treatment and prevention of the metastatic spread of thyroid cancer . HH1-1, a polysaccharide isolated and purified from safflower oil, blocks the interaction between Gal-3 and EGFR and inhibits the growth of pancreatic cancer cells . Interestingly, curcumin, a well-known natural bioactive substance derived from the rhizome of the ginger family, also showed strong inhibitory activity against Gal-3 overexpression, implying the underlying use in oncologic applications .
Immediately following the preclinical advances in laboratories, a number of Gal-1 and Gal3 inhibitors have already been applied in clinical trials (Table 5). Most of the 13 trials (updated till Dec 2022) have employed either galectin inhibitors alone (e.g. GM-CT-01 and GR-MD-02) or in combination with chemotherapeutic agents (e.g. 5-fluorouracil) or monoclonal antibodies (e.g. ipilimumab or pembrolizumab) for treatment of solid tumors. In these trials, multicenter phase I or II trials have been initiated for various types of tumors, including non-small cell lung cancer, metastatic melanoma, squamous cell head and neck cancer, colorectal cancer, bile duct and gallbladder cancer, breast cancer, prostate cancer, metastatic melanoma and diffuse large B-cell lymphoma. So far, only two Phase I trials (NCT00054977 and NCT02117362) and one Phase II trial (NCT01681823) have been completed. Unfortunately, over half of the studies have been withdrawn or terminated due to poor treatment effects or lack of funding, suggesting that not all galectin inhibitors are suitable for all tumor types and that their efficacy may vary depending on the protocol design and the galectin expression profile in each individual.
Overview of autophagy
In all eukaryotic cells, autophagy is highly conserved event that cells degrade their damaged organelles and macromolecules through lysosomes to maintain normal biological homeostasis and basic cell activities. Essential roles of autophagy include protecting cells from damaged proteins, shielding cell organelles from toxins, maintaining cell metabolism and energy homeostasis, and promoting cell survival, particularly in stressful conditions (e.g., starvation, hypoxia, endoplasmic reticulum stress, infection, and lack of growth factors) [99,100,101]. Depending on the pathway of cellular material passaging to the lysosome, macroautophagy, microautophagy and chaperone-mediated autophagy are often classified . Since macroautophagy is the primary autophagic process in eukaryotic cells, it is thereafter simply referred as autophagy.
The autophagic pathway
Autophagy is a complex multistep process involving more than 30 core autophagy-related (ATG) proteins. We here summarized the autophagic pathway briefly into six phases (Fig. 2.): initiation phase, precursor nucleation phase, extension phase, autophagosome maturation phase, autophagosome-lysosome fusion phase and cargo degradation and recycling phase.
In the initiation stage, the AMP-activated protein kinase (AMPK) and the mammalian target of rapamycin (mTOR) signaling pathways are the pivotal regulators [103, 104]. Activation of AMPK, a key cellular energy sensor, leads to the inactivation of mTOR pathway, and subsequently switches on autophagy. Once mTORC1 kinase activity is suppressed under situations such as nutrient deprivation or stress, AMPK and mTOR together target the Unc-51 like kinase (ULK) complex directly, which activates and initiates the formation of autophagosomes . This is followed by the recruitment of other effector proteins through phosphorylation and activation of the phosphoinositide 3-kinase (PI3K) complex that mediates phagocytic vesicle nucleation . After the formation of autophagic precursors, the phagocytic vesicle membrane continues to extend until it completely envelops the contents to be degraded. During this process, the implication of two ubiquitin-like protein modification systems, ATG12-ATG5 and LC3-PE, are the hallmark events [107, 108]. With the extension and closure of the autophagosome, mature autophagosomes are formed . The progressive removal of ATG proteins from the outer membrane of autophagosomes allows the recruitment of proteins responsible for lysosomal delivery and proteins mediating the fusion with lysosomes . Next, the autophagosomal outer membrane fuses with the lysosomal membrane to form autophagic lysosomes . Finally, the autophagosomal endosomal membrane and contents are degraded into small molecules by acid hydrolases within the lysosome and the recovered nutrients are released back into the cytoplasm for reuse, i.e. the recycling phase .
Role of autophagy in cancer
Autophagy has been characterized to regulate tumorigenesis, tumor metastasis, tumor stem cells, and treatment resistance . Despite that a couple of autophagy modulators have been used to treat cancer, the dual role of autophagy, as tumor suppressor or promoter, has limited its use in clinical applications and is a major reason for treatment failure [111, 112]. Alternatively, regulation of autophagic flux may provide other options for autophagy-based therapy strategies. On top of that, inhibitors (Chloroquine, Hydroxychloroquine, GNS651 and Clarithromycin) or inducers (Rapamycin, Temsirolimus, Everolimus and Metformin) of autophagy can be applied for cancer treatment separately, depending on the respective cancers and the specific stage of tumorigenesis [113, 114].
Autophagy as tumor suppressor
Autophagy inhibition may lead to genomic instability and the aggregation of damaged organelles and proteins generated by tumor cells . In this sense, autophagy is initially believed to inhibit tumor progression during the early stages of cancer development. Of note, EMT promotion caused by autophagy inhibition have been widely reported in cancer research and cancer therapy [116, 117]. Beclin1 is involved in the autophagosome formation and exerts an antitumor effect by promoting apoptosis in cancer cells, and deficiency in Beclin1 has been shown to promote tumor cell proliferation in several cancers (e.g. ovarian, breast and prostate cancers) [118, 119]. Moreover, Beclin1 expression has been shown to be downregulated in a variety of malignant tumors including glioblastoma, liver cancer, osteosarcoma, and cervical squamous carcinoma . Some other ATG genes and proteins have also been suggested to be tumor suppressors since deletion of ATG5 and ATG7 induces the development of benign liver tumors in mice . Interestingly, ATG7 conditional knockout mice developed multiple tumors in the liver, and additional knockdown of the autophagy receptor protein p62 reversed this phenotype, suggesting that p62 accumulation due to autophagy inhibition promotes tumor formation . Tissue-specific knockdown of ATG5 or ATG7 also promotes lung cancer driven by oncogenic mutations . In addition, overexpression of ULK2 induces glioblastoma autophagy and inhibits astrocyte transformation and tumor growth . These studies suggest that autophagy plays a tumor-suppressive role in several tumors.
Autophagy as tumor promoter
In contrast, autophagy for a long time has been described as a pro-survival mechanism in most advanced tumors, by promoting tumor to adapt to different stressed conditions such as hypoxia or nutritional deficiency, thus mediating tumor progression . The expression of hypoxia-inducible factor 1α (HIF1α) is induced under hypoxia, which mediates AMPK activation and mTOR inhibition, thus promoting autophagy and cell survival . The autophagic cargo adapter p62 is also downregulated when hypoxia-induced autophagy occurs, leading to activation of Ras/ERK signaling and enhanced cell proliferation . Moreover, the autophagy gene ATG5 is highly expressed in gastric and prostate cancer [127, 128], ATG7 is abundantly present in bladder cancer , and conditional knockout of autophagy gene FIP200 shows reduced mammary tumorigenesis . Autophagy promotes EMT and metastasis of hepatocellular carcinoma and pancreatic tumor cell [131, 132], and it also facilitates the oncogenic RAS-mediated tumorigenesis, which together indicates the pro-tumorigenic role of autophagy . Apart from the role of promoting tumor cell proliferation, autophagy also participates in tumor metastasis and stemness maintenance of cancer stem cells (CSCs), and the autophagic fluxes were enhanced in specific types of CSCs . Taken together, autophagy can also promote tumorigenesis and tumor progression, implying that autophagy inhibition may also be conducive in the treatment for particular cancers.
Targeting autophagy in cancer therapy
As mentioned above, due to the dual role of autophagy in tumorigenesis, both autophagy activators and inhibitors have been used in preclinical and clinical studies (Fig. 2.). Typical autophagy-inducers include classic mTOR1 inhibitors such as Rapamycin (RAPA, Sirolimus), RAPA analogs Temsirolimus (CCI-779) and Everolimus (RAD001), all of which have been used to treat different cancers . Several autophagy-stimulatory compounds have also been identified to show anticancer effects, including metformin that upregulates AMPK, resveratrol that activates silent information regulator 1 (SIRT1), and perifosine that inhibits AKT/mTOR signaling . Although induction of cytoprotective autophagy in early-stage tumors may inhibit cancer progression, enhanced autophagy resulting from chemotherapy and radiotherapy has been shown to contribute to therapeutic resistance in several cancers . In a number of advanced tumors, increased autophagic activity promotes the survival of tumor cells, thus inhibition of autophagy may enable the blockade of tumor progression. In this context, majorities of current anticancer strategies have been inclined to achieve autophagy inhibition or to combine autophagy inhibition with other treatment approaches.
Given the complexities of the autophagic process, various autophagy inhibitors targeting different stages of the autophagic process have been established. Wortmannin, 3-methyladenine (3-MA), and LY294002 block autophagosome formation by targeting class III PI3K at the autophagy initiation stage, and chloroquine (CQ), hydroxychloroquine (HCQ), monensin, and bafilomycin A1 are able to inhibit autophagy by preventing the fusion of autophagosomes and lysosomes . Among these inhibitors, only CQ and HCQ are currently available for the clinical use . Facing the immediate demand in clinical cancer therapy, several new inhibitors of autophagy are being tested in preclinical trials, with 3-MA, SAR405, Lys05, ROC-325, Spautin-1, MM124 and MM137 being most promising [114, 137]. These compounds are targeting different autophagic process, and further studies are needed to determine their clinical value in cancer treatment. Apart from drugs that targeting autophagic process directly, other approaches including microRNA, nanoparticles, natural products like luteolin, also exert autophagy-regulation and anti-tumor effects [138,139,140]. Since the roles of autophagy are bidirectional and may vary in distinct cancer types, the uses of autophagy inducers or inhibitors should be customized in the future cancer treatments.
Galectin and autophagy
Galectin regulation of autophagy
A growing body of evidence supports the relationship between galectins and autophagy. A seminal work in 2012 reported by Teresa Thurston revealed the significance of Gal-8 in autophagy, which has thereafter drawn more attention to Gal-autophagy interaction. Under physiological conditions, Gal-8 protects cells from bacterial invasion by regulating the integrity of endosomes and lysosomes and recruiting the autophagic cargo receptor NDP52 to activate antibacterial autophagy [141, 142]. Similarly, the galectin-mediated protective mechanisms also play a role in resistance to the invasion of viruses . By specifically interacting with the selective autophagy adaptor TAX1BP1, Gal-8 enables macrophages to effectively target mycobacterium tuberculosis for selective autophagy . This finding suggests that Gal-8 may serve as a potential target for the treatment of tuberculosis. In addition, Gal-7 interacts with the bacterial autophagy receptor Tollip and also regulates bacterial autophagy along with other autophagy receptors that are recruited . In contrast to Gal-7 and Gal-8, cellular accumulation of Gal-3 leads to a strong anti-autophagic response, by sensing glycosylation changes on cell surface and modulating cellular responses through differential recognition of glycans on ruptured phagosomal membranes  (Fig. 3A.).
Galectins also modulate autophagy in processing with endosomal damage associated with lysosomal dysfunction (Fig. 3B.). In response to damaged endosomes, TRIM16 and Gal-3 interact in a ULK1-dependent way to mobilize the key autophagy regulators ATG16, ULK1 and Beclin1, and activate selective autophagy [147, 148]. Lysosomal damage is one of the strongest stimulators of autophagy, but how lysosomal membrane damage activates autophagy is not fully understood. It has been shown that, in response to lysosomal damage, Gal-8 inhibits mTOR activity through Ragulator-Rag signaling, while Gal-9 activates AMPK in a Gal-9-ubiquitination dependent manner to induce autophagy [149,150,151].
Galectin-autophagy association in cancer
In contrast to extensive studies on galectin or autophagy alone, the function of Galectin-regulated autophagy in tumor biology has been less elucidated. Shikonin induces reactive oxygen species (ROS) accumulation in colorectal cancer cells, which promotes Gal-1 expression and dimerization and suppresses autophagic flux by blocking the degradation of autophagolysosomes, and eventually stimulates autophagic cell death . In addition, Gal-1 has been reported to promotes resistance to radiotherapy and chemotherapy of tumor cells (Fig. 4.), and downregulation of Gal-1 could suppress autophagy and enhance the sensitivity of neuroblastoma to cisplatin treatment . Similarly, Gal-1 secreted by hepatoma cells causes autophagic flux by blocking AKT-mTOR activities in an autocrine manner. Autophagy induced by Gal-1 alleviates the damage of mitochondrial membranes and cell death under cisplatin treatment, which results in cisplatin resistance. Therefore, Gal-1 inhibition by thiobisgalactoside significantly increases the senstivity of cisplatin in hepatocellular carcinoma treatment . Notably, knockdown of Gal-1 also increased the sensitivity of malignant melanoma and glioblastoma to temozolomide, yet without inducing apoptosis or autophagy [155, 156].
Gal-3 may negatively regulates autophagy in melanoma cells, which is evidence by reduced the pro-survival function autophagy and consequent treatment resistance . In pancreatic cell lines, Gal-3 is involved in the regulation of autophagy to maintain intracellular homeostasis under extreme conditions such as hypoxia and nutrient deficiency .
Recombinant Galectin-9 (rGal-9), through its internalization and accumulation in lysosomes, causes lysosome swelling and inhibited fusion of autophagosome and lysosomes, leading to boosted cell death in KRAS-mutant colon cancer .
Gal-8 has recently been suggested as a novel biomarker for autophagy-related tumors in glioblastoma (GBM) . However, to our knowledge, whether Gal-8 regulates tumor growth through autophagy-dependent mechanisms is unknown. Our group found that Gal-8 expression correlates with the progression of GBM and that hypoxia induces GBM autophagy to promote tumorigenesis through Gal-8 (data unpublished). Our data demonstrate that inhibiting Gal-8 to further block autophagy in hypoxic microenvironment could attenuate the cell growth in GBM both in vitro and in vivo.
Conclusions and Outlook
Half a century ago, galectins were discovered as a glycan-binding protein. We now have known better about this family as more physiological and pathological functions of galectins are gradually revealed. Considering the broad roles of galectins in tumorigenesis, the trend of galectins being potential diagnostic markers and therapeutic targets in cancers has been well recognized. Here in this review, we summarize the roles of galectins in normal and cancerous cells, highlight the clinical applications of galectin inhibitors in cancer research, and introduce autophagy as a vital mediator in galectin regulated tumorigenesis, aiming to shed lights on galectin-autophagy targeted anticancer strategies.
There are still a number of concerns when galectins-targeted cancer treatments are to be applied into human patients. Most preclinical research is conducted in cultured cells and animal models, which are not able to fully recapitulate the complex environments within human tumors, in addition to the high heterogeneity across tumor types. Even though more than a dozen of clinical trials has started, unfortunately, failures and inclusive results seem inevitable. Furthermore, tumor cells express more than one galectin, and factors such as subcellular localization and posttranscriptional modifications of galectins add extra complexity onto the specificity of galectin in tumors. Therefore, tumor-specific galectin-targeting is crucial before therapy commences. Another aspect to take into account is that the cancer stem cells hidden in the solid tumor, may show distinct galectin expression profiles and sensitivity to galectin intervention compared to general tumor cells, providing the strategic possibility of targeting the ‘ancestral’ cells to block potential malignancy in their successor tumor cells. Additionally, increasing evidence are unveiling the intracellular roles of galectins in either mediating signaling transduction initiated from outer space or maintaining cell hemostasis. Intracellular galectins are to be particularly targeted for drug design other than being neglected, since the majority of current inhibitors are designed to block the extracellular functions of galectins.
Targeting the autophagic pathway in anticancer therapies also appears to be promising, although not many autophagy-based compounds are currently in use for treating cancer. As expected, the dual role of autophagy leads to the decision whether autophagy in tumor cells should be inhibited or induced hard to make, and specific research is warranted to determine which types of cancer patients would benefit from autophagy-based strategies, considering our current knowledge that potential molecular mechanisms and specific targets of autophagy very likely diverge in different cancers. While the notion has been being more and more accepted that current clinical trials are meant to evaluate inhibition of autophagy alone or in combination with other treatments, encouragingly, a large body of evidence has shown that galectins are key autophagy inducers, suggesting that therapies targeting galectins in combination with other modulators such as autophagy in tumor progression may open new window to halt cancer progression.
Together, as galectin-based preclinical and clinical studies are emerging in cancer treatment, more applicable signature molecules of galectins as biomarkers for diagnosis, galectin-targeting drug design, cancer-specific drug delivery, in conjunction with combinations of autophagy-targeted agents, probably could provide better strategies to achieve precise dual-targeting in specific cancer type and various stages of tumorigenesis. These complexities and challenges are assumed to equally be exploited for the early diagnosis and successful treatments for cancers.
Availability of data and materials
Carbohydrate recognition domains
Po66 carbohydrate-binding protein
Focal adhesion kinase
Activated leukocyte cell adhesion molecule
T-cell immunoglobulin and mucin structural domain protein 3
Programmed cell death ligand 1
Clustered regularly interspaced short palindromic repeats
Modified citrus pectin
AMP-activated protein kinase
Mammalian target of rapamycin
Unc-51 like kinase
Hypoxia-inducible factor 1α
Cancer stem cells
Silent information regulator 1
Reactive oxygen species
Vasta GR. Galectins as pattern recognition receptors: structure, function, and evolution. Adv Exp Med Biol. 2012;946:21–36.
Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell. 1994;76(4):597–8.
Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci. 2007;64(13):1679–700.
Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5(1):29–41.
Li CH, Chang YC, Chan MH, Yang YF, Liang SM, Hsiao M. Galectins in cancer and the microenvironment: functional roles, therapeutic developments, and perspectives. Biomedicines. 2021;9(9):1159.
Yin Z, Pascual C, Klionsky DJ. Autophagy: machinery and regulation. Microb Cell. 2016;3(12):588–96.
Mehrpour M, Esclatine A, Beau I, Codogno P. Overview of macroautophagy regulation in mammalian cells. Cell Res. 2010;20(7):748–62.
Ariosa AR, Lahiri V, Lei Y, Yang Y, Yin Z, Zhang Z, et al. A perspective on the role of autophagy in cancer. Biochim Biophys Acta Mol Basis Dis. 2021;1867(12):166262.
Camuzard O, Santucci-Darmanin S, Carle GF, Pierrefite-Carle V. Autophagy in the crosstalk between tumor and microenvironment. Cancer Lett. 2020;490:143–53.
Johannes L, Jacob R, Leffler H. Galectins at a glance. J Cell Sci. 2018;131(9):jcs208884.
Brinchmann MF, Patel DM, Iversen MH. The Role of Galectins as Modulators of Metabolism and Inflammation. Mediators Inflamm. 2018;2018:9186940.
Wu NL, Liu FT. The expression and function of galectins in skin physiology and pathology. Exp Dermatol. 2018;27(3):217–26.
Advedissian T, Deshayes F, Poirier F, Grandjean C, Viguier M. Galectins, a class of unconventional lectins. Med Sci (Paris). 2015;31(5):499–505.
Grozdanovic MM, Doyle CB, Liu L, Maybruck BT, Kwatia MA, Thiyagarajan N, et al. Charcot-Leyden crystal protein/galectin-10 interacts with cationic ribonucleases and is required for eosinophil granulogenesis. J Allergy Clin Immunol. 2020;146(2):377-89 e10.
Su J, Gao J, Si Y, Cui L, Song C, Wang Y, et al. Galectin-10: a new structural type of prototype galectin dimer and effects on saccharide ligand binding. Glycobiology. 2018;28(3):159–68.
Wdowiak K, Francuz T, Gallego-Colon E, Ruiz-Agamez N, Kubeczko M, Grochola I, et al. Galectin targeted therapy in oncology: current knowledge and perspectives. Int J Mol Sci. 2018;19(1):210.
Shimada C, Xu R, Al-Alem L, Stasenko M, Spriggs DR, Rueda BR. Galectins and ovarian cancer. Cancers (Basel). 2020;12(6):1421.
Cho Y, Lee YB, Lee JH, Lee DH, Cho EJ, Yu SJ, et al. Modified AS1411 aptamer suppresses hepatocellular carcinoma by up-regulating galectin-14. PLoS ONE. 2016;11(8):e0160822.
Kaminker JD, Timoshenko AV. Expression, regulation, and functions of the galectin-16 gene in human cells and tissues. Biomolecules. 2021;11(12):1909.
Compagno D, Jaworski FM, Gentilini L, Contrufo G, Gonzalez Perez I, Elola MT, et al. Galectins: major signaling modulators inside and outside the cell. Curr Mol Med. 2014;14(5):630–51.
Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood. 2009;113(9):1957–66.
Vladoiu MC, Labrie M, St-Pierre Y. Intracellular galectins in cancer cells: potential new targets for therapy (Review). Int J Oncol. 2014;44(4):1001–14.
Chou FC, Chen HY, Kuo CC, Sytwu HK. Role of galectins in tumors and in clinical immunotherapy. Int J Mol Sci. 2018;19(2):430.
Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT, et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 2002;23(6):313–20.
Balan V, Nangia-Makker P, Raz A. Galectins as cancer biomarkers. Cancers (Basel). 2010;2(2):592–610.
Soukup V, Kalousova M, Capoun O, Sobotka R, Breyl Z, Pesl M, et al. Panel of urinary diagnostic markers for non-invasive detection of primary and recurrent urothelial urinary bladder carcinoma. Urol Int. 2015;95(1):56–64.
Wiest I, Alexiou C, Kuhn C, Schulze S, Kunze S, Mayr D, et al. Expression of different carbohydrate tumour markers and galectins 1 and 3 in normal squamous and malignant epithelia of the upper aaerodigestive tract. Anticancer Res. 2012;32(5):2023–9.
Cousin JM, Cloninger MJ. The role of galectin-1 in cancer progression, and synthetic multivalent systems for the study of galectin-1. Int J Mol Sci. 2016;17(9):1566.
Sharanek A, Burban A, Hernandez-Corchado A, Madrigal A, Fatakdawala I, Najafabadi HS, et al. Transcriptional control of brain tumor stem cells by a carbohydrate binding protein. Cell Reports. 2021;36(9):109647.
Roff CF, Wang JL. Endogenous lectins from cultured cells. Isolation and characterization of carbohydrate-binding proteins from 3T3 fibroblasts. J Biol Chem. 1983;258(17):10657–63.
Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, et al. Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. Cancer Immunol Res. 2015;3(4):412–23.
Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997;57(23):5272–6.
Elad-Sfadia G, Haklai R, Balan E, Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem. 2004;279(33):34922–30.
Veschi V, Petroni M, Cardinali B, Dominici C, Screpanti I, Frati L, et al. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells. PLoS ONE. 2012;7(11):e49139.
Fukumori T, Oka N, Takenaka Y, Nangia-Makker P, Elsamman E, Kasai T, et al. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res. 2006;66(6):3114–9.
Chen Y, Xu J, Pan W, Xu X, Ma X, Chu Y, et al. Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells. Thorac Cancer. 2022;13(13):1961–73.
Ebrahim AH, Alalawi Z, Mirandola L, Rakhshanda R, Dahlbeck S, Nguyen D, et al. Galectins in cancer: carcinogenesis, diagnosis and therapy. Ann Transl Med. 2014;2(9):88.
Zhu H, Liu D, Cheng L, Liu J, Wang G, Li H, et al. Prognostic value and biological function of galectins in malignant glioma. Front Oncol. 2022;12:834307.
Manero-Ruperez N, Martinez-Bosch N, Barranco LE, Visa L, Navarro P. The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic Cancer. Cells. 2020;9(3):689.
Guo Y, Shen R, Yu L, Zheng X, Cui R, Song Y, et al. Roles of galectin-3 in the tumor microenvironment and tumor metabolism (Review). Oncol Rep. 2020;44(5):1799–809.
de Oliveira JT, Ribeiro C, Barros R, Gomes C, de Matos AJ, Reis CA, et al. Hypoxia up-regulates galectin-3 in mammary tumor progression and metastasis. PLoS One. 2015;10(7):e0134458.
Ikemori R, Machado CML, Nonogaki S, Verinaud L, Chammas R. Hypoxia-induced galectin-3 plays a role in the survival of nutrient-deprived glioblastoma cells. Glycobiology. 2009;19(11):1318.
Haudek KC, Spronk KJ, Voss PG, Patterson RJ, Wang JL, Arnoys EJ. Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim Biophys Acta. 2010;1800(2):181–9.
van den Brule FA, Waltregny D, Liu FT, Castronovo V. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer. 2000;89(4):361–7.
Honjo Y, Inohara H, Akahani S, Yoshii T, Takenaka Y, Yoshida J, et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res. 2000;6(12):4635–40.
Hadari YR, Paz K, Dekel R, Mestrovic T, Accili D, Zick Y. Galectin-8. A new rat lectin, related to galectin-4. J Biol Chem. 1995;270(7):3447–53.
Henno S, Brichory F, Langanay T, Desrues B, Bidon N, Delaval P, et al. Expression of Po66-CBP, a galectin-8, in different types of primary and secondary broncho-pulmonary tumors. Oncol Rep. 2002;9(1):177–80.
Gopalkrishnan RV, Roberts T, Tuli S, Kang D, Christiansen KA, Fisher PB. Molecular characterization of prostate carcinoma tumor antigen-1, PCTA-1, a human galectin-8 related gene. Oncogene. 2000;19(38):4405–16.
Danguy A, Rorive S, Decaestecker C, Bronckart Y, Kaltner H, Hadari YR, et al. Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system. Histol Histopathol. 2001;16(3):861–8.
Cludts S, Decaestecker C, Mahillon V, Chevalier D, Kaltner H, Andre S, et al. Galectin-8 up-regulation during hypopharyngeal and laryngeal tumor progression and comparison with galectin-1, -3 and -7. Anticancer Res. 2009;29(12):4933–40.
Wollina U, Graefe T, Feldrappe S, Andre S, Wasano K, Kaltner H, et al. Galectin fingerprinting by immuno- and lectin histochemistry in cutaneous lymphoma. J Cancer Res Clin Oncol. 2002;128(2):103–10.
Cada Z, Smetana K, Lacina L, Plzakova Z, Stork J, Kaltner H, et al. Immunohistochemical fingerprinting of the network of seven adhesion/growth-regulatory lectins in human skin and detection of distinct tumour-associated alterations. Folia Biol. 2009;55(4):145–52.
Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H, et al. Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut. 2002;50(3):392–401.
Su ZZ, Lin J, Shen R, Fisher PE, Goldstein NI, Fisher PB. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. Proc Natl Acad Sci U S A. 1996;93(14):7252–7.
Videla-Richardson GA, Morris-Hanon O, Torres NI, Esquivel MI, Vera MB, Ripari LB, et al. Galectins as emerging Glyco-Checkpoints and therapeutic targets in glioblastoma. Int J Mol Sci. 2022;23(1):316.
Levy Y, Arbel-Goren R, Hadari YR, Eshhar S, Ronen D, Elhanany E, et al. Galectin-8 functions as a matricellular modulator of cell adhesion. J Biol Chem. 2001;276(33):31285–95.
Ferragut F, Cagnoni AJ, Colombo LL, Sanchez Terrero C, Wolfenstein-Todel C, Troncoso MF, et al. Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth. Biochim Biophys Acta Mol Cell Res. 2019;1866(8):1338–52.
Wada J, Kanwar YS. Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem. 1997;272(9):6078–86.
Tureci O, Schmitt H, Fadle N, Pfreundschuh M, Sahin U. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin’s disease. J Biol Chem. 1997;272(10):6416–22.
Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem. 1998;273(27):16976–84.
Kobayashi T, Kuroda J, Ashihara E, Oomizu S, Terui Y, Taniyama A, et al. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia. 2010;24(4):843–50.
Jafari SM, Nazri A, Shabani M, Balajam NZ, Aghaei M. Galectin-9 induces apoptosis in OVCAR-3 ovarian cancer cell through mitochondrial pathway. Res Pharm Sci. 2018;13(6):557–65.
Kobayashi K, Morishita A, Iwama H, Fujita K, Okura R, Fujihara S, et al. Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest. Oncol Rep. 2015;34(4):1761–70.
Akashi E, Fujihara S, Morishita A, Tadokoro T, Chiyo T, Fujikawa K, et al. Effects of galectin-9 on apoptosis, cell cycle and autophagy in human esophageal adenocarcinoma cells. Oncol Rep. 2017;38(1):506–14.
Nobumoto A, Nagahara K, Oomizu S, Katoh S, Nishi N, Takeshita K, et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology. 2008;18(9):735–44.
Fu H, Liu Y, Xu L, Liu W, Fu Q, Liu H, et al. Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma. Tumour Biol. 2015;36(8):5791–9.
Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245–52.
Knudsen AM, Rudkjobing SJ, Sorensen MD, Dahlrot RH, Kristensen BW. Expression and Prognostic Value of the Immune Checkpoints Galectin-9 and PD-L1 in Glioblastomas. J Neuropathol Exp Neurol. 2021;80(6):541–51.
Oda Y, Herrmann J, Gitt MA, Turck CW, Burlingame AL, Barondes SH, et al. Soluble lactose-binding lectin from rat intestine with two different carbohydrate-binding domains in the same peptide chain. J Biol Chem. 1993;268(8):5929–39.
Chiu ML, Parry DA, Feldman SR, Klapper DG, O’Keefe EJ. An adherens junction protein is a member of the family of lactose-binding lectins. J Biol Chem. 1994;269(50):31770–6.
Wooters MA, Hildreth MB, Nelson EA, Erickson AK. Immunohistochemical characterization of the distribution of galectin-4 in porcine small intestine. J Histochem Cytochem. 2005;53(2):197–205.
Huflejt ME, Leffler H. Galectin-4 in normal tissues and cancer. Glycoconj J. 2004;20(4):247–55.
Conde-Rodriguez I, Delgado-Lopez G, Armenta-Castro E, Ramirez-Diaz I, Anaya-Ruiz M, Gutierrez-Quiroz CT, et al. Evaluation of serum levels and expression of galectin-4 in cervical cancer. Biomed Res Int. 2020;2020:1–9.
Belo AI, van der Sar AM, Tefsen B, van Die I. Galectin-4 Reduces Migration and Metastasis Formation of Pancreatic Cancer Cells. PLoS ONE. 2013;8(6):e65957.
Satelli A, Rao PS, Thirumala S, Rao US. Galectin-4 functions as a tumor suppressor of human colorectal cancer. Int J Cancer. 2011;129(4):799–809.
Hayashi T, Saito T, Fujimura T, Hara K, Takamochi K, Mitani K, et al. Galectin-4, a novel predictor for lymph node metastasis in lung adenocarcinoma. PLoS ONE. 2013;8(12):e81883.
Magnaldo T, Bernerd F, Darmon M. Galectin-7, a human 14-kDa S-lectin, specifically expressed in keratinocytes and sensitive to retinoic acid. Dev Biol. 1995;168(2):259–71.
Pergialiotis V, Papoutsi E, Androutsou A, Tzortzis AS, Frountzas M, Papapanagiotou A, et al. Galectins-1,-3,-7,-8 and-9 as prognostic markers for survival in epithelial ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Obstet. 2021;152(3):299–307.
Kopitz J, Andre S, von Reitzenstein C, Versluis K, Kaltner H, Pieters RJ, et al. Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells. Oncogene. 2003;22(40):6277–88.
Takata T, Ishigaki Y, Shimasaki T, Tsuchida H, Motoo Y, Hayashi A, et al. Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro. Oncol Rep. 2012;28(6):1968–76.
Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, Zhao Q, et al. Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res. 2011;17(22):7035–46.
Ji P, Gong Y, Jin ML, Wu HL, Guo LW, Pei YC, et al. In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer. Sci Adv. 2022;8(26):eabl8247.
Katzenmaier EM, Fuchs V, Warnken U, Schnolzer M, Gebert J, Kopitz J. Deciphering the galectin-12 protein interactome reveals a major impact of galectin-12 on glutamine anaplerosis in colon cancer cells. Exp Cell Res. 2019;379(2):129–39.
Peng F, Huang Y, Li MY, Li GQ, Huang HC, Guan R, et al. Dissecting characteristics and dynamics of differentially expressed proteins during multistage carcinogenesis of human colorectal cancer. World J Gastroentero. 2016;22(18):4515–28.
Hashimoto I, Kimura Y, Oue N, Hiroshima Y, Aoyama T, Rino Y, et al. Identification of a biomarker combination for survival stratification in pstage ii/iii gastric cancer after curative resection. Cancers. 2022;14(18):4427.
Sethi A, Sanam S, Alvala R, Alvala M. An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016-present). Expert Opin Ther Pat. 2021;31(8):709–21.
Blanchard H, Bum-Erdene K, Hugo MW. Inhibitors of galectins and implications for structure-based design of galectin-specific therapeutics. Aust J Chem. 2014;67(12):1763–79.
Ito K, Scott SA, Cutler S, Dong LF, Neuzil J, Blanchard H, et al. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis. 2011;14(3):293–307.
Koonce NA, Griffin RJ, Dings RPM. Galectin-1 Inhibitor OTX008 induces tumor vessel normalization and tumor growth inhibition in human head and neck squamous cell carcinoma models. Int J Mol Sci. 2017;18(12):2671.
Salomonsson E, Thijssen VL, Griffioen AW, Nilsson UJ, Leffler H. The anti-angiogenic peptide Anginex greatly enhances galectin-1 binding affinity for glycoproteins. J Biol Chem. 2011;286(16):13801–4.
Miller MC, Klyosov A, Mayo KH. The alpha-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain. Glycobiology. 2009;19(9):1034–45.
Fang T, Liu DD, Ning HM, Liu D, Sun JY, Huang XJ, et al. Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3. Acta Pharmacol Sin. 2018;39(12):1885–93.
Streetly MJ, Maharaj L, Joel S, Schey SA, Gribben JG, Cotter FE. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood. 2010;115(19):3939–48.
Lee JJ, Hsu YC, Li YS, Cheng SP. Galectin-3 inhibitors suppress Anoikis resistance and invasive capacity in thyroid cancer cells. Int J Endocrinol. 2021;2021:5583491.
Zhang L, Wang P, Qin Y, Cong Q, Shao C, Du Z, et al. RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways. Oncogene. 2017;36(9):1297–308.
Yao YL, Zhou LS, Liao WF, Chen HJ, Du ZY, Shao CH, et al. HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway. Carbohyd Polym. 2019;204:111–23.
Dumic J, Dabelic S, Flogel M. Curcumin - A potent inhibitor of galectin-3 expression. Food Technol Biotech. 2002;40(4):281–7.
Dings RPM, Kumar N, Miller MC, Loren M, Rangwala H, Hoye TR, et al. Structure-Based Optimization of Angiostatic Agent 6DBF7, an Allosteric Antagonist of Galectin-1. J Pharmacol Exp Ther. 2013;344(3):589–99.
Yorimitsu T, Klionsky DJ. Autophagy: molecular machinery for self-eating. Cell Death Differ. 2005;12 Suppl 2(Suppl 2):1542–52.
Yun CW, Lee SH. The roles of autophagy in cancer. Int J Mol Sci. 2018;19(11):3466.
Gatica D, Lahiri V, Klionsky DJ. Cargo recognition and degradation by selective autophagy. Nat Cell Biol. 2018;20(3):233–42.
Mizushima N, Levine B. Autophagy in mammalian development and differentiation. Nat Cell Biol. 2010;12(9):823–30.
Rabanal-Ruiz Y, Otten EG, Korolchuk VI. mTORC1 as the main gateway to autophagy. Essays Biochem. 2017;61(6):565–84.
Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011;13(9):1016–23.
McAlpine F, Williamson LE, Tooze SA, Chan EY. Regulation of nutrient-sensitive autophagy by uncoordinated 51-like kinases 1 and 2. Autophagy. 2013;9(3):361–73.
Bento CF, Renna M, Ghislat G, Puri C, Ashkenazi A, Vicinanza M, et al. Mammalian autophagy: how does it work? Annu Rev Biochem. 2016;85:685–713.
Geng JF, Klionsky DJ. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. EMBO Rep. 2008;9(9):859–64.
Romanov J, Walczak M, Ibiricu I, Schuchner S, Ogris E, Kraft C, et al. Mechanism and functions of membrane binding by the Atg5-Atg12/Atg16 complex during autophagosome formation. Embo J. 2012;31(22):4304–17.
Tanida I. Autophagosome Formation and Molecular Mechanism of Autophagy. Antioxid Redox Sign. 2011;14(11):2201–14.
Diao JJ, Liu R, Rong YG, Zhao ML, Zhang J, Lai Y, et al. ATG14 promotes membrane tethering and fusion of autophagosomes to endolysosomes. Nature. 2015;520(7548):563–6.
Yun CW, Jeon J, Go G, Lee JH, Lee SH. The Dual Role of Autophagy in Cancer Development and a Therapeutic Strategy for Cancer by Targeting Autophagy. Int J Mol Sci. 2020;22(1):179.
Ashrafizadeh M, Paskeh MDA, Mirzaei S, Gholami MH, Zarrabi A, Hashemi F, et al. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. J Exp Clin Cancer Res. 2022;41(1):105.
SalimiJeda A, Ghabeshi S, Gol Mohammad Pour Z, Jazaeri EO, Araiinejad M, Sheikholeslami F, et al. Autophagy modulation and cancer combination therapy: a smart approach in cancer therapy. Cancer Treat Res Commun. 2022;30:100512.
Buzun K, Gornowicz A, Lesyk R, Bielawski K, Bielawska A. Autophagy modulators in cancer therapy. Int J Mol Sci. 2021;22(11):5804.
Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, et al. Autophagy in malignant transformation and cancer progression. Embo J. 2015;34(7):856–80.
Chen HT, Liu H, Mao MJ, Tan Y, Mo XQ, Meng XJ, et al. Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy. Mol Cancer. 2019;18(1):101.
Rojas-Sanchez G, Cotzomi-Ortega I, Pazos-Salazar NG, Reyes-Leyva J, Maycotte P. Autophagy and its relationship to epithelial to mesenchymal transition: when autophagy inhibition for cancer therapy turns counterproductive. Biology (Basel). 2019;8(4):71.
Qu XP, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003;112(12):1809–20.
Takahashi Y, Coppola D, Matsushita N, Cualing HD, Sun M, Sato Y, et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol. 2007;9(10):1142–51.
Marinkovic M, Sprung M, Buljubasic M, Novak I. Autophagy modulation in cancer: current knowledge on action and therapy. Oxid Med Cell Longev. 2018;2018:8023821.
Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 2011;25(8):795–800.
Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, Mathew R, et al. Autophagy sustains mitochondrial glutamine metabolism and growth of Braf(V600E)-driven lung tumors. Cancer Discov. 2013;3(11):1272–85.
Shukla S, Patric IRP, Patil V, Shwetha SD, Hegde AS, Chandramouli BA, et al. Methylation silencing of ULK2, an autophagy gene, is essential for astrocyte transformation and tumor growth. J Biol Chem. 2014;289(32):22306–18.
Guo JY, Xia B, White E. Autophagy-mediated tumor promotion. Cell. 2013;155(6):1216–9.
Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, et al. Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma. Can Res. 2012;72(7):1773–83.
Pursiheimo JP, Rantanen K, Heikkinen PT, Johansen T, Jaakkola PM. Hypoxia-activated autophagy accelerates degradation of SQSTM1/p62. Oncogene. 2009;28(3):334–44.
Ge J, Chen ZH, Huang J, Chen JX, Yuan WJ, Deng ZH, et al. Upregulation of autophagy-related Gene-5 (ATG-5) is associated with Chemoresistance in human gastric cancer. Plos One. 2014;9(10):e110293.
Kim MS, Song SY, Lee JY, Yoo NJ, Lee SH. Expressional and mutational analyses of ATG5 gene in prostate cancers. APMIS. 2011;119(11):802–7.
Zhu JL, Li Y, Tian ZX, Hua XH, Gu JY, Li JX, et al. ATG7 Overexpression Is Crucial for Tumorigenic Growth of Bladder Cancer In Vitro and In Vivo by Targeting the ETS2/miRNA196b/FOXO1/p27 Axis. Mol Ther-Nucl Acids. 2017;7:299–313.
Wei HJ, Wei S, Gan BY, Peng X, Zou WP, Guan JL. Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev. 2011;25(14):1510–27.
Li J, Yang B, Zhou Q, Wu YZ, Shang D, Guo Y, et al. Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelialmesenchymal transition. Carcinogenesis. 2013;34(6):1343–51.
Zhu HT, Wang DQ, Zhang LR, Xie XD, Wu YY, Liu YF, et al. Upregulation of autophagy by hypoxia-inducible factor-1 alpha promotes EMT and metastatic ability of CD133(+) pancreatic cancer stem-like cells during intermittent hypoxia. Oncol Rep. 2014;32(3):935–42.
Lock R, Kenifi CM, Leidal AM, Salas E, Debnath J. Autophagy-dependent production of secreted factors facilitates oncogenic RAS-Driven Invasion. Cancer Discov. 2014;4(4):466–79.
Aguilar-Gallardo C, Zamorano M, Farias JG, Quevedo KD. Understanding autophagy role in cancer stem cell development. Mol Biol Rep. 2022;49(7):6741–51.
Farhan M, Silva M, Li S, Yan FX, Fang JK, Peng TM, et al. The role of FOXOs and autophagy in cancer and metastasis-Implications in therapeutic development. Med Res Rev. 2020;40(6):2089–113.
Ganzleben I, Neurath MF, Becker C. Autophagy in cancer therapy-molecular mechanisms and current clinical advances. Cancers. 2021;13(21):5575.
Mohsen S, Sobash PT, Algwaiz GF, Nasef N, Al-Zeidaneen SA, Karim NA. Autophagy agents in clinical trials for cancer therapy: a brief review. Curr Oncol. 2022;29(3):1695–708.
Paskeh MDA, Entezari M, Clark C, Zabolian A, Ranjbar E, Farahani MV, et al. Targeted regulation of autophagy using nanoparticles: New insight into cancer therapy. Biochim Biophys Acta Mol Basis Dis. 2022;1868(3):166326.
Ashrafizadeh M, Ahmadi Z, Farkhondeh T, Samarghandian S. Autophagy regulation using luteolin: new insight into its anti-tumor activity. Cancer Cell Int. 2020;20(1):537.
Ashrafizadeh M, Zarrabi A, Orouei S, Kiavash H, Hakimi A, Amirhossein Z, et al. MicroRNA-mediated autophagy regulation in cancer therapy: The role in chemoresistance/chemosensitivity. Eur J Pharmacol. 2021;892:173660.
Thurston TLM, Wandel MP, von Muhlinen N, Foeglein A, Randow F. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nature. 2012;482(7385):414-U1515.
Kim BW, Hong SB, Kim JH, Kwon DH, Song HK. Structural basis for recognition of autophagic receptor NDP52 by the sugar receptor galectin-8. Nat Commun. 2013;4:1613.
Pied N, Daussy CF, Denis Z, Ragues J, Faure M, Iggo R, et al. TBK1 is part of a galectin 8 dependent membrane damage recognition complex and drives autophagy upon Adenovirus endosomal escape. PLoS Pathog. 2022;18(7):e1010736.
Bell SL, Lopez KL, Cox JS, Patrick KL, Watson RO. Galectin-8 senses phagosomal damage and recruits selective autophagy adapter TAX1BP1 To Control Mycobacterium tuberculosis Infection in Macrophages. Mbio. 2021;12(4):e0187120.
Lin CY, Nozawa T, Minowa-Nozawa A, Toh H, Hikichi M, Iibushi J, et al. Autophagy Receptor Tollip Facilitates Bacterial Autophagy by Recruiting Galectin-7 in Response to Group A Streptococcus Infection. Front Cell Infect Mi. 2020;10:583137.
Weng IC, Chen HL, Lo TH, Lin WH, Chen HY, Hsu DK, et al. Cytosolic galectin-3 and-8 regulate antibacterial autophagy through differential recognition of host glycans on damaged phagosomes. Glycobiology. 2018;28(6):392–405.
Chauhan S, Kumar S, Jain A, Ponpuak M, Mudd MH, Kimura T, et al. TRIMs and Galectins Globally Cooperate and TRIM16 and Galectin-3 Co-direct Autophagy in Endomembrane Damage Homeostasis. Dev Cell. 2016;39(1):13–27.
Kumar S, Chauhan S, Jain A, Ponpuak M, Choi SW, Mudd M, et al. Galectins and TRIMs directly interact and orchestrate autophagic response to endomembrane damage. Autophagy. 2017;13(6):1086–7.
Jia JY, Abudu YP, Claude-Taupin A, Gu YX, Kumar S, Choi SW, et al. Galectins control MTOR and AMPK in response to lysosomal damage to induce autophagy. Autophagy. 2019;15(1):169–71.
Jia JY, Abudu YP, Claude-Taupin A, Gu YX, Kumar S, Choi SW, et al. Galectins Control mTOR in Response to Endomembrane Damage. Mol Cell. 2018;70(1):120–35.
Jia JY, Bissa B, Brecht L, Allers L, Choi SW, Gu YX, et al. AMPK, a Regulator of Metabolism and Autophagy, Is Activated by Lysosomal Damage via a Novel Galectin-Directed Ubiquitin Signal Transduction System. Mol Cell. 2020;77(5):951–69.
Zhang N, Peng F, Wang YJ, Yang L, Wu FB, Wang XY, et al. Shikonin induces colorectal carcinoma cells apoptosis and autophagy by targeting galectin-1/JNK signaling axis. Int J Biol Sci. 2020;16(1):147–61.
Gao J, Wang WY. Knockdown of galectin-1 facilitated cisplatin sensitivity by inhibiting autophagy in neuroblastoma cells. Chem Biol Interact. 2019;297:50–6.
Su YC, Davuluri GVN, Chen CH, Shiau DC, Chen CC, Chen CL, et al. Galectin-1-Induced autophagy facilitates cisplatin resistance of hepatocellular carcinoma. Plos One. 2016;11(2):e0148408.
Mathieu V, Le Mercier M, De Neve N, Sauvage S, Gras T, Roland I, et al. Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol. 2007;127(10):2399–410.
Lefranc F. Evidence of Galectin-1 involvement in glioma pro-angiogenic and pro-migratory effects and chemoresistance. Eur J Cancer. 2011;47:S21.
Bustos SO, da Silva Pereira GJ, de Freitas SR, Gil CD, Zanatta DB, Smaili SS, et al. Galectin-3 sensitized melanoma cell lines to vemurafenib (PLX4032) induced cell death through prevention of autophagy. Oncotarget. 2018;9(18):14567–79.
da Silva ANF, de Sousa LM, Consonni SR, Pitta MGD, Carvalho HF, Rego MJBD. Galectin-3 expression in pancreatic cell lines under distinct autophagy-inducing stimulus. Microsc Microanal. 2020;26(6):1187–97.
Wiersma VR, de Bruyn M, Wei YW, van Ginkel RJ, Hirashima M, Niki T, et al. The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. Autophagy. 2015;11(8):1373–88.
Wang YL, Zhao WJ, Xiao Z, Guan GF, Liu X, Zhuang MH. A risk signature with four autophagy-related genes for predicting survival of glioblastoma multiforme. J Cell Mol Med. 2020;24(7):3807–21.
This work was supported by grants from the National Natural Science Foundation of China (31900692, 32070961) to Chuanzhou Li, the China Postdoctoral Science Foundation (2022M711253) to Hongtao Zhu and the postdoctoral innovation research position funding of Hubei province (2022) to Hongtao Zhu.
Ethics approval and consent to participate
Consent for publication
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Liu, D., Zhu, H. & Li, C. Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy. Biomark Res 11, 22 (2023). https://doi.org/10.1186/s40364-023-00466-9
- Cancer therapy
- Clinical trials